search
Back to results

Ceritinib Rare Indications Study in ALK+ Tumors

Primary Purpose

Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Ceritinib (LDK378)
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tumors With Aberrations in ALK focused on measuring ALK, GBM, hematological malignancy, anaplastic lymphoma kinase, glioblastoma, anaplastic large cell lymphoma, IMT, inflammatory myofibroblastic tumor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient has a histologically or cytologically confirmed diagnosis of ALK positive (ALK+) tumor other than Non-Small Cell Lung Cancer (NSCLC).
  • Patient must provide an archival or fresh tumor tissue before the first dose of the study drug for ALK testing at a Novartis designated central laboratory.
  • Patient has WHO Performance Status (PS) ≤ 2
  • Patient must have received at least one line of prior systemic treatment for recurrent, locally advanced and/or metastatic disease, and may have discontinued for:

    • Disease progression as defined by RECIST 1.1 for solid tumors; by RANO for GBM and by Cheson assessment criteria for lymphoma, or
    • Intolerance described as any discontinuation due to an AE of any grade despite appropriate supportive treatment
  • Patient has at least one measurable lesion as defined by appropriate guidelines. A lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation.
  • Patient has received no chemotherapy, immunotherapy or stem cell therapy at least 4 weeks before starting ceritinib
  • Radiotherapy and prior ALK inhibitors must be stopped at least 1 week prior to starting ceritinib
  • Recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (Common Terminology Criteria for Adverse Events [CTCAE] v4.03).

Exclusion Criteria:

  • Patient has ALK+lung cancer
  • Patient with symptomatic CNS metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
  • Patient with acute or chronic GI disease that may significantly alter the absorption of ceritinib.
  • Patient with a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
  • Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis.
  • Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months).
  • Patient has evidence of active viral hepatitis, including Hepatitis A, B or C (testing for viral hepatitis is not mandatory).
  • Patient has known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory).

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Inflammatory myofibroblastic tumor (IMT)

Anaplastic large cell lymphoma (ALCL)

Glioblastoma (GBM)

Any other ALK-positive tumor

Arm Description

Patients diagnosed with IMT with a confirmed translocation involving the ALK gene

Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive

Patients with GBM with a translocation involving the ALK gene

Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).

Outcomes

Primary Outcome Measures

Disease Control Rate (DCR) Based on Investigator Assessments for Participants With at Least 16 Weeks of Treatment
The DCR is defined as the percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) at 16 weeks from the start of ceritinib treatment. The assessment criteria are: Solid Tumors (RECIST 1.1., Response Evaluation Criteria in Solid Tumors); GBM (RECIST 1.1 and RANO, Response Evaluation in Neuro-Oncology); Hematologic tumors (Cheson).

Secondary Outcome Measures

Overall Response Rate (ORR) Per Investigator Assessment
ORR is defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local assessment according to RECIST 1.1, RANO or Cheson hematological criteria.
Duration of Response (DOR) Per Investigator Assessment
DOR is defined as the time from date of first documented CR or PR to date of first documented disease progression or death due to any cause
Time to Response (TTR) Per Investigator Assessment
TTR is defined as the time from date of the first dose to date of first documented response (CR or PR)
Progression Free Survival (PFS) Per Investigator Assessments
PFS is defined as the time from the date of first dose of ceritinib to the date of first documented disease progression or death from any cause
Percent of Participant Deaths During Treatment and Follow-up
Deaths due to any cause during treatment and 30 day follow-up

Full Information

First Posted
May 29, 2015
Last Updated
December 17, 2019
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT02465528
Brief Title
Ceritinib Rare Indications Study in ALK+ Tumors
Official Title
A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Terminated
Study Start Date
May 6, 2016 (Actual)
Primary Completion Date
August 20, 2018 (Actual)
Study Completion Date
August 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration (and/or overexpression in some diseases).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor, Glioblastoma
Keywords
ALK, GBM, hematological malignancy, anaplastic lymphoma kinase, glioblastoma, anaplastic large cell lymphoma, IMT, inflammatory myofibroblastic tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Depending on the tumor type, subjects were to be enrolled into one of the following parallel arms: ALCL (anaplastic large cell lymphoma); IMT (inflammatory myofibroblastic tumor); glioblastoma (GBM), and any other ALK+ tumor. If there were 5 or more subjects of the same tumor type in the "Any other ALK+ tumor" arm, then a separate arm was to be opened for that specific tumor type.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inflammatory myofibroblastic tumor (IMT)
Arm Type
Experimental
Arm Description
Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
Arm Title
Anaplastic large cell lymphoma (ALCL)
Arm Type
Experimental
Arm Description
Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
Arm Title
Glioblastoma (GBM)
Arm Type
Experimental
Arm Description
Patients with GBM with a translocation involving the ALK gene
Arm Title
Any other ALK-positive tumor
Arm Type
Experimental
Arm Description
Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
Intervention Type
Drug
Intervention Name(s)
Ceritinib (LDK378)
Intervention Description
Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
Primary Outcome Measure Information:
Title
Disease Control Rate (DCR) Based on Investigator Assessments for Participants With at Least 16 Weeks of Treatment
Description
The DCR is defined as the percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) at 16 weeks from the start of ceritinib treatment. The assessment criteria are: Solid Tumors (RECIST 1.1., Response Evaluation Criteria in Solid Tumors); GBM (RECIST 1.1 and RANO, Response Evaluation in Neuro-Oncology); Hematologic tumors (Cheson).
Time Frame
Baseline up to approximately 16 weeks
Secondary Outcome Measure Information:
Title
Overall Response Rate (ORR) Per Investigator Assessment
Description
ORR is defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local assessment according to RECIST 1.1, RANO or Cheson hematological criteria.
Time Frame
Baseline, every 8 weeks until disease progression or end of treatment, whichever came first assessed up to approximately 84 weeks
Title
Duration of Response (DOR) Per Investigator Assessment
Description
DOR is defined as the time from date of first documented CR or PR to date of first documented disease progression or death due to any cause
Time Frame
Baseline, every 8 weeks until disease progression or end of treatment, whichever came first, assessed up to approximately 84 weeks
Title
Time to Response (TTR) Per Investigator Assessment
Description
TTR is defined as the time from date of the first dose to date of first documented response (CR or PR)
Time Frame
Baseline, every 8 weeks until disease progression or end of treatment, whichever came first, assessed up to approximately 84 weeks
Title
Progression Free Survival (PFS) Per Investigator Assessments
Description
PFS is defined as the time from the date of first dose of ceritinib to the date of first documented disease progression or death from any cause
Time Frame
Baseline, every 8 weeks until disease progression or death from any cause, assessed for up to approximately 84 weeks
Title
Percent of Participant Deaths During Treatment and Follow-up
Description
Deaths due to any cause during treatment and 30 day follow-up
Time Frame
Baseline up to approximately 84 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient has a histologically or cytologically confirmed diagnosis of ALK positive (ALK+) tumor other than Non-Small Cell Lung Cancer (NSCLC). Patient must provide an archival or fresh tumor tissue before the first dose of the study drug for ALK testing at a Novartis designated central laboratory. Patient has WHO Performance Status (PS) ≤ 2 Patient must have received at least one line of prior systemic treatment for recurrent, locally advanced and/or metastatic disease, and may have discontinued for: Disease progression as defined by RECIST 1.1 for solid tumors; by RANO for GBM and by Cheson assessment criteria for lymphoma, or Intolerance described as any discontinuation due to an AE of any grade despite appropriate supportive treatment Patient has at least one measurable lesion as defined by appropriate guidelines. A lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation. Patient has received no chemotherapy, immunotherapy or stem cell therapy at least 4 weeks before starting ceritinib Radiotherapy and prior ALK inhibitors must be stopped at least 1 week prior to starting ceritinib Recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (Common Terminology Criteria for Adverse Events [CTCAE] v4.03). Exclusion Criteria: Patient has ALK+lung cancer Patient with symptomatic CNS metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms. Patient with acute or chronic GI disease that may significantly alter the absorption of ceritinib. Patient with a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease. Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis. Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months). Patient has evidence of active viral hepatitis, including Hepatitis A, B or C (testing for viral hepatitis is not mandatory). Patient has known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory).
Facility Information:
Facility Name
Novartis Investigative Site
City
Brno
State/Province
Czech Republic
ZIP/Postal Code
656 53
Country
Czechia
Facility Name
Novartis Investigative Site
City
Copenhagen
ZIP/Postal Code
DK-2100
Country
Denmark
Facility Name
Novartis Investigative Site
City
Lyon Cedex
ZIP/Postal Code
69373
Country
France
Facility Name
Novartis Investigative Site
City
Saint-Herblain Cédex
ZIP/Postal Code
44805
Country
France
Facility Name
Novartis Investigative Site
City
Strasbourg
ZIP/Postal Code
F 67085
Country
France
Facility Name
Novartis Investigative Site
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Facility Name
Novartis Investigative Site
City
Milano
State/Province
MI
ZIP/Postal Code
20133
Country
Italy
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Novartis Investigative Site
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Facility Name
Novartis Investigative Site
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ceritinib Rare Indications Study in ALK+ Tumors

We'll reach out to this number within 24 hrs